Literature DB >> 16489930

Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.

Gurmeet Kaur1, Melinda Hollingshead, Susan Holbeck, Vesna Schauer-Vukasinović, Richard F Camalier, Alexander Dömling, Seema Agarwal.   

Abstract

Tubulysin A (tubA) is a natural product isolated from a strain of myxobacteria that has been shown to depolymerize microtubules and induce mitotic arrest. The potential of tubA as an anticancer and antiangiogenic agent is explored in the present study. tubA shows potent antiproliferative activity in a panel of human cancer cell lines irrespective of their multidrug resistance properties. It induces apoptosis in cancer cells but not in normal cells and shows significant potential antiangiogenic properties in several in vitro assays. It is efficacious in initial animal studies using a hollow fibre assay with 12 different human tumour cell lines. This study suggests that both in vitro and preclinical profiles of tubA may translate into clinically useful anticancer properties.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16489930      PMCID： PMC1462728          DOI： 10.1042/BJ20051735

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  38 in total

Review 1.  Interactions of antimitotic peptides and depsipeptides with tubulin.

Authors:  Ernest Hamel
Journal:  Biopolymers       Date:  2002       Impact factor: 2.505

Review 2.  Recent advances in the field of tubulin polymerization inhibitors.

Authors:  Helge Prinz
Journal:  Expert Rev Anticancer Ther       Date:  2002-12       Impact factor: 4.512

Review 3.  Apoptosis-targeted therapies for cancer.

Authors:  John C Reed
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

4.  Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.

Authors:  J H Schiller; G Bittner
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

5.  Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  J Med Chem       Date:  2002-12-19       Impact factor: 7.446

6.  HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Authors:  Frank Loganzo; Carolyn M Discafani; Tami Annable; Carl Beyer; Sylvia Musto; Malathi Hari; Xingzhi Tan; Carolyn Hardy; Richard Hernandez; Michelle Baxter; Thiruvikraman Singanallore; Gulnaz Khafizova; Marianne S Poruchynsky; Tito Fojo; James A Nieman; Semiramis Ayral-Kaloustian; Arie Zask; Raymond J Andersen; Lee M Greenberger
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

7.  Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol).

Authors:  B H Long; J M Carboni; A J Wasserman; L A Cornell; A M Casazza; P R Jensen; T Lindel; W Fenical; C R Fairchild
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

8.  Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.

Authors:  V K Ngan; K Bellman; D Panda; B T Hill; M A Jordan; L Wilson
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Authors:  Nicola J Mabjeesh; Daniel Escuin; Theresa M LaVallee; Victor S Pribluda; Glenn M Swartz; Michelle S Johnson; Margaret T Willard; Hua Zhong; Jonathan W Simons; Paraskevi Giannakakou
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

Review 10.  Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.

Authors:  D W Miles
Journal:  Breast Cancer Res       Date:  2001-10-11       Impact factor: 6.466
View more
  21 in total

1.  Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

Authors:  William C Floyd; Gopal K Datta; Shinichi Imamura; Heidi M Kieler-Ferguson; Katherine Jerger; Andrew W Patterson; Megan E Fox; Francis C Szoka; Jean M J Fréchet; Jonathan A Ellman
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

Review 2.  Antivascular actions of microtubule-binding drugs.

Authors:  Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

3.  Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.

Authors:  S Rath; J Liebl; R Fürst; A Ullrich; J L Burkhart; U Kazmaier; J Herrmann; Rolf Müller; M Günther; L Schreiner; E Wagner; A M Vollmar; S Zahler
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds.

Authors:  Christopher T Walsh; Robert V O'Brien; Chaitan Khosla
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-31       Impact factor: 15.336

Review 5.  Role of the cytoskeleton in formation and maintenance of angiogenic sprouts.

Authors:  Kayla J Bayless; Greg A Johnson
Journal:  J Vasc Res       Date:  2011-04-04       Impact factor: 1.934

6.  The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2.

Authors:  Oluwafunmilayo F Lamidi; Monica Sani; Paolo Lazzari; Matteo Zanda; Ian N Fleming
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-30       Impact factor: 4.553

7.  Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Authors:  Carolyn A Leverett; Sai Chetan K Sukuru; Beth C Vetelino; Sylvia Musto; Kevin Parris; Jayvardhan Pandit; Frank Loganzo; Alison H Varghese; Guoyun Bai; Bin Liu; Dingguo Liu; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-08-26       Impact factor: 4.345

8.  (+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9.

Authors:  Christian Freise; Wolfram Trowitzsch-Kienast; Martin Ruehl; Ulrike Erben; Daniel Seehofer; Ki Young Kim; Martin Zeitz; Rajan Somasundaram
Journal:  Invest New Drugs       Date:  2011-11-03       Impact factor: 3.850

9.  Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues.

Authors:  Ranganathan Balasubramanian; Bhooma Raghavan; Adrian Begaye; Dan L Sackett; Robert A Fecik
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

10.  Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.

Authors:  Leanna R Staben; Shang-Fan Yu; Jinhua Chen; Gang Yan; Zijin Xu; Geoffrey Del Rosario; Jeffrey T Lau; Luna Liu; Jun Guo; Bing Zheng; Josefa Dela Cruz-Chuh; Byoung-Chul Lee; Rachana Ohri; Wenwen Cai; Hongxiang Zhou; Katherine R Kozak; Keyang Xu; Gail D Lewis Phillips; Jiawei Lu; John Wai; Andrew G Polson; Thomas H Pillow
Journal:  ACS Med Chem Lett       Date:  2017-09-05       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.